Mao, Ying
Bai, Hai Xia
Li, Bin
Xu, Xiao Lin
Gao, Fei
Zhang, Zhi Bao
Jonas, Jost B. http://orcid.org/0000-0003-2972-5227
Article History
Received: 14 February 2018
Revised: 10 July 2018
Accepted: 26 July 2018
First Online: 15 August 2018
Compliance with ethical standards
:
: Jost B. Jonas: Patent holder with Biocompatibles UK Ltd. (Franham, Surrey, UK) (Title: Treatment of eye diseases using encapsulated cells encoding and secreting neuroprotective factor and / or anti-angiogenic factor; Patent number: 20120263794), and Patent application with University of Heidelberg (Heidelberg, Germany) (Title: Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia; European Patent Number: 3070101). This does not alter our adherence to the journal’s policies on sharing data and materials. All other authors: None.
: According to the Declaration of Helsinki, the study was approved by the Medical Ethics Committee of the Beijing Tongren Hospital, waiving the necessity of a written informed consent by the patients since the eyes had been enucleated up to 50 years before the study was started.